REM Sleep Behaviour Disorder (RBD) is a parasomnia characterized by the loss of physiological muscle atonia during rapid eye movement sleep, leading to dream-enactment. Idiopathic RBD is strongly associated with α-synucleinopathies and frequently precedes the onset of motor or cognitive symptoms by several years, making it a valuable prodromal marker of neurodegenerative diseases, such as Parkinson’s disease. Given the substantial healthcare burden of neurodegenerative diseases, early identification of at-risk individuals is essential to enable timely interventions, positioning RBD as a critical target for early detection. However, the current gold standard for RBD diagnosis is video-polysomnography, an expensive and resource-intensive procedure, unsuitable for large-scale screening.